AURORA, Ontario, Jan. 7 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. today announced that John Docherty, president and chief operating officer, will present at Biotech Showcase 2010 at 9:40 a.m. PST on January 13, 2010 at the Marines' Memorial Club and Hotel in San Francisco. Mr. Docherty will provide an overview of the Company's leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on January 13, 2010.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is listed on the TSX and FSE under the symbol "HBP" and on the OTCQX International Market under the symbol "HXBPF".
CONTACT: Investor Relations, Robert Flamm, Ph.D., Russo Partners LLC,
+1-212-845-4226, robert.flamm@russopartnersllc.com; or Media Relations, Ian
Stone, Russo Partners LLC, +1-619-814-3510, Fax: +1-619-955-5318,
ian.stone@russopartnersllc.com
Web site: http://www.helixbiopharma.com/
